"Only JQ1 and RVX208 are showing BRD2/4 while the others have different Human Gene. JQ1 is pre-clinical.  Does that mean that RVX208, since it is proven safe AND has a Human Gene BRD2/4, is the best hope of all these molecules?"

The article identifies several interactions between viral proteins and human proteins. One of the MANY interactions identified was the interaction between viral envelope protein (E) and the human proteins BRD2 and BRD4. However, if you look at the paper you will appreciate that beyond the E interaction with BRD2/4 they also highlight over 300 other high confidence SARS-CoV-2-human protein-protein interactions between various viral proteins and other human proteins (encoded by the corresponding human genes). Among the >300 interactions, they identify 66 that they consider druggable based upon the existence of currently FDA-approved drugs, drugs in clinical trials and/or preclinical compounds. They state that "that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays." So we don't yet know yet if any of these drugs will be helpful (or harmful) in terms of SARS-CoV-2.

Furthermore, there are many many many clinical and pre-clinical BET bromodomain inhibitors beyond JQ1 and RVX-208. Just because they mention only 2 in Table 1a (and a few more in Figure 4) doesn't mean that these particular BET inhibitors are more effective or hold more potential than others. Other BET inhibitors not mentioned in Table 1a and Figure 4 may prove to be superior. They were just providing some examples; it was not meant to be an exhaustive list. It would be impractical for them to test all BET inhibitors in their infection assays. Hopefully they do indeed test RVX-208!

"And I believe E, refers to experiments being done outside of the cells or body (Ex-Vivo)."

No, E refers to the viral envelope protein.

BDAZ